In regard to treatment response, multiple studies have demonstrated that increased PD-L1 expression on EGFRm NSCLC cells predicts worse outcomes with TKIs but improved outcome with ICI therapy (91–93). The gene discussed is CD274; the disease is non-small cell lung carcinoma.